Financial Performance - For the six months ended June 30, 2024, the company reported revenue of HKD 25,921,000, an increase of 3.2% compared to HKD 25,109,000 for the same period in 2023[2] - Gross profit for the same period was HKD 14,034,000, representing a gross margin of 54.2%, up from HKD 12,210,000 in 2023[2] - The net loss for the six months ended June 30, 2024, was HKD 1,609,000, a significant improvement from a net loss of HKD 4,704,000 in the prior year[3] - Basic and diluted loss per share for the period was HKD 0.23, compared to HKD 0.69 for the same period in 2023[2] - The net loss for the period was approximately HKD 1,609,000, a reduction of about 65.80% compared to HKD 4,704,000 in the previous year[36] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 133,585,000, a decrease from HKD 136,201,000 as of December 31, 2023[4] - The company's cash and cash equivalents stood at HKD 65,356,000, down from HKD 66,826,000 at the end of 2023[4] - Non-current liabilities decreased to HKD 25,815,000 from HKD 28,038,000 in the previous period[5] - Current liabilities increased slightly to HKD 66,153,000 from HKD 64,551,000 as of December 31, 2023[5] - The company reported a total equity of HKD 41,617,000, down from HKD 43,612,000 at the end of 2023[4] - The group's liabilities as of June 30, 2024, are approximately HKD 49.840 million, down from HKD 50.759 million as of December 31, 2023, resulting in a leverage ratio of approximately 37.31%[40] - The net current assets as of June 30, 2024, are approximately HKD 13.016 million, compared to HKD 15.467 million as of December 31, 2023[41] - The current ratio as of June 30, 2024, is approximately 1.20, down from 1.24 as of December 31, 2023[41] - The debt-to-equity ratio as of June 30, 2024, is approximately 127%, an increase from 123% as of December 31, 2023[42] Revenue Breakdown - The healthcare and medical business generated revenue of HKD 18,377,000 for the six months ended June 30, 2024, up from HKD 15,814,000 in the same period of 2023, reflecting a growth of 16.2%[10] - The beauty and wellness business reported revenue of HKD 7,544,000 for the six months ended June 30, 2024, down from HKD 9,295,000 in the same period of 2023, indicating a decline of 18.8%[10] - The healthcare and medical business segment's revenue increased by approximately 16.21% from HKD 15.81 million to HKD 18.38 million[27] - The group's total revenue for the period was approximately HKD 25,921,000, representing a slight increase of about 3.23% compared to HKD 25,109,000 in the previous year[30] Expenses - Direct costs and operating expenses decreased by approximately 7.85% to HKD 11,887,000 from HKD 12,899,000 in the previous year[31] - Selling expenses decreased by approximately 9.26% to HKD 6,682,000 from HKD 7,364,000 in the previous year[33] - Administrative expenses decreased by approximately 25.59% to HKD 11,763,000 from HKD 15,808,000 in the previous year[34] - Employee benefits expenses for the six months ended June 30, 2024, amounted to HKD 12,488,000, compared to HKD 11,861,000 for the same period in 2023, representing an increase of 5.3%[14] - Financing costs decreased by approximately 8.72% to HKD 1,026,000 from HKD 1,124,000 in the previous year[35] Corporate Governance - The company has confirmed compliance with the corporate governance code, except for the absence of an internal audit function due to operational scale[52] - The audit committee consists of three independent non-executive directors, with one member holding professional accounting qualifications[54] - The interim financial statements have been reviewed by the audit committee and are deemed to comply with applicable accounting standards and listing rules[54] - The company has adopted the standard code for securities trading by directors and confirmed adherence to it for the six months ending June 30, 2024[53] Future Outlook and Investments - The company continues to focus on providing healthcare and wellness services, with ongoing investments in new products and technologies[6] - The total capital expenditure budget for the relocation of Yiyang Hospital was approximately RMB 17.3 million (HKD 19.5 million)[38] - As of June 30, 2024, approximately RMB 16.4 million (HKD 18.5 million) has been utilized for the relocation of Yiyang Hospital, with the remaining budget expected to be fully utilized by Q1 2025[38] Dividend and Share Capital - The company does not recommend any dividend payment for the six months ended June 30, 2024, consistent with the previous period[18] - The company’s total issued and paid-up share capital remained unchanged at 659,894,693 shares as of June 30, 2024, consistent with the previous period[25] Compliance and Reporting - The interim results announcement has been published on the Hong Kong Stock Exchange and the company's website, with the full interim report to be sent to shareholders by September 30, 2024[55] - The company has not reported any revenue from a single customer exceeding 10% of total revenue for the periods ended June 30, 2024, and 2023[10]
格林国际控股(02700) - 2024 - 中期业绩